Serum Institute Of India

Expects positive news on indigenous Mpox vaccine within a year: Poonawalla

Mpox cases have been confirmed among children and adults in more than a dozen African countries, and a new form of the virus is spreading

Billionaire Yohan Poonawalla buys South Bombay mansion for over Rs 400 cr

The standalone property, spanning approximately 30,000 sq ft., joins a prestigious collection of mansions in the area that are typically priced between Rs 400-750 crore.

Mankind Pharma frontrunner to acquire Bharat Serums in $1.5 bn deal

Mankind Pharma rose as much as 1.2 per cent following Thursday's Bloomberg News report. The shares are up about 6.5 per cent this year and 10 per cent in the past 12 months

Serum Institute rolls out new high efficacy malaria vaccine in Africa

A new high efficacy malaria vaccine co-developed by the Serum Institute of India (SII) and the University of Oxford was officially rolled out on Monday when Cote d'Ivoire in West Africa became the first country to begin administering R21/Matrix-M. The vaccine, which was granted World Health Organisation (WHO) approval last year, is said to have undergone a rigorous regulatory process and clinical assessment and was found to be highly effective and affordable. As a low-dose vaccine, it can be manufactured at speed and scale which is seen as critical to stemming the spread of the mosquito-borne disease. Reducing the malaria burden is finally within sight. Today's start of the R21/Matrix-M vaccine roll-out marks a monumental milestone after years of incredible work with our partners at Oxford and Novavax, said SII CEO Adar Poonawalla. At Serum, we believe that it is every person's right to have access to affordable and essential disease prevention. That's why we have committed to ...

World's largest vaccine maker Serum Institute sees demand doubling in 5 yrs

The world's largest vaccine maker currently has the capacity to produce 3 billion doses of all types of vaccines each year, but only sells about 1.5 billion doses annually

Serum Institute ships its first set of malaria vaccine doses to Africa

The vaccine has been developed in collaboration with the University of Oxford and Novavax's Matrix-M adjuvant

Covid vaccine makers gear up to launch new-generation jabs in India

India currently does not have any XBB 1.5 variant-based vaccines in the market

SII to acquire 20% stake in needle-free tech company IntegriMedical

The collaboration leverages SII's manufacturing and distribution strength with IntegriMedical's innovative technology

Not producing, distributing Covishield since December 2021: Serum Institute

AstraZeneca Covid vaccine row: As of April 30, 2024, over 1.7 billion doses of the Covishield vaccine has been administered in India

Serum Institute responds for first time on Covishield amid safety row

Serum Institute of India says it stopped manufacturing Covishield since December 2021

SC to hear Serum's plea challenging amendment to IT Act on May 17

With this plea, it also challenged the Bombay High Court's order that dismissed its petition against a 2016 amendment to the Income Tax Act

PM Modi missing from Covid certificates after Covishield row: Here's why

Ministry of Health and Family Welfare informed that PM Modi's photo was removed from Covid certificates due to the Model Code of Conduct (MCC) in effect for the ongoing Lok Sabha polls

Astrazeneca row: Only 7 in a million at risk of TTS, says ex-ICMR scientist

Former ICMR scientist Raman Gangakhedkar said the risk is highest after the initial dose, eventually decreasing with subsequent doses

Parents to sue Serum Institute over daughter's alleged Covishield death

Father says that AstraZeneca's admission of vaccine's rare side effect is 'too late'

AstraZeneca vaccine: From its origin to side effects, all you need to know

Manufactured first in 2021, the AstraZeneca vaccine, known in India as Covishield, has been facing scrutiny over the years, with many countries banning it back in 2021 itself

Polio vax supplies: Health secy visits OPV maker Bilthoven's Dutch plant

Bilthoven Biologicals is an arm of Serum Institute of India that makes oral polio vax

SII prepares to supply India's entire IPV requirement in 3-4 months

IPV has been introduced in UIP as part of Global Polio end-game strategy since November 2015 initially in six states, which was expanded across the country by April 2016

Bharat Biotech, Bilthoven Biologicals collaborate for oral polio vaccines

Bharat Biotech on Tuesday said it has collaborated with the Netherlands-based Bilthoven Biologicals B.V, a wholly-owned arm of Serum Institute of India, to strengthen production and supply security of oral polio vaccines. An agreement has been signed between the two partners under which Bharat Biotech will procure drug substances for the production of oral polio vaccines (OPVs) to be supplied within India and globally, the company said in a statement. Through this collaboration, Bharat Biotech and Bilthoven Biologicals (BBio) will jointly obtain regulatory approvals and licences required to commercially manufacture OPVs in India for global supplies from drug substances manufactured in the Netherlands at BBio, it added. "This collaboration...exemplifies cooperation between vaccine companies, ensuring a secure supply of oral polio vaccines and fortifies the nation's mission to eradicate polio," Bharat Biotech Executive Chairman Krishna Ella said. Serum Institute of India CEO Adar ...

Serum looks beyond Covid with new vaccines for malaria, dengue: CEO

Serum produces AstraZeneca's Covid-19 vaccine under the brand name Covishield in India, and also makes Novavax's protein-based Covid shots

Serum Institute joins CEPI network to make vaccines for disease outbreaks

$30 mn invesment will expand company's ability to swiftly supply investigational vaccines for the Global South